Keytruda's Core Patents and Coverage
Keytruda (pembrolizumab), Merck's blockbuster PD-1 inhibitor for cancers like melanoma and lung cancer, is protected by multiple US patents listed in the FDA's Orange Book. The primary composition-of-matter patent (US 8,354,509) covers the antibody structure and expires in 2028, with pediatric exclusivity extending it to January 2029. Method-of-use patents extend protection for specific indications up to 2035, including combinations like Keytruda + chemotherapy [1][2]. These block generics and biosimilars until expiry or invalidation.
How Keytruda Patents Shape Drug Development
Pharma companies planning Keytruda biosimilars must design around these patents via "patent dance" under the Biologics Price Competition and Innovation Act (BPCIA). This involves licensing negotiations or litigation; for instance, Samsung Bioepis and Viatris challenged Merck's patents in 2021, settling for a 2028 US launch [1]. Developers face high R&D costs ($100M+ for biosimilars) and delays from Paragraph IV challenges, which trigger 30-month stays on FDA approval [2].
Litigation and Challenges to Keytruda Patents
Merck has defended aggressively: a 2023 PTAB ruling invalidated some formulation patents, but key antibody claims held. Ongoing suits against Amgen, Organon, and others could shorten exclusivity. Europe sees earlier biosimilar entry (e.g., Bioeq's 2024 approval), pressuring US timelines [1][3]. Patent thickets—over 100 Orange Book listings—deter entry, maintaining Keytruda's $25B+ annual revenue.
Impact on Pricing and Market Access
Patents sustain high list prices (~$11,000/month), limiting access in low-income regions. Post-patent, biosimilars could cut costs 20-30%, as seen with Humira. Patients and payers watch for compulsory licensing in places like India, where Natco launched a version in 2023 despite disputes [2].
Biosimilar Timelines and Alternatives
US biosimilars unlikely before 2028; first wave expected 2029-2030 from Mylan, Sandoz. Competitors like Opdivo (Bristol Myers) face similar issues but offer alternatives now. Track updates on DrugPatentWatch.com for expiry details and challenges [1].
Sources
[1]: DrugPatentWatch.com - Keytruda Patents
[2]: FDA Orange Book - Pembrolizumab
[3]: USPTO PTAB Decisions - Merck v. Samsung